Andrew Doan
Contact
COVID-19 outcomes in children, adolescents and young adults with cancer Int J Cancer. 2022 Dec 01; 151(11):1913-1924. . View in PubMed
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium Pediatr Blood Cancer. 2022 10; 69(10):e29812. . View in PubMed
Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution Pediatr Blood Cancer. 2022 05; 69(5):e29601. . View in PubMed
The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma J Pediatr Hematol Oncol. 2022 03 01; 44(2):e605-e608. . View in PubMed
Characterization of PAX5 intragenic tandem multiplication in pediatric B-lymphoblastic leukemia by optical genome mapping Blood Adv. 2022 06 14; 6(11):3343-3346. . View in PubMed
A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies Cancer Genet. 2021 06; 254-255:25-33. . View in PubMed
Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL J Pediatr Hematol Oncol. 2020 11; 42(8):e839-e844. . View in PubMed
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia Blood Adv. 2019 07 09; 3(13):1926-1929. . View in PubMed
Hypogammaglobulinemia due to CAR T-cell therapy Pediatr Blood Cancer. 2018 04; 65(4). . View in PubMed
